---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-23-000031"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:11:50.205359+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Prothena reports Q3 net income of $21.9M; revenue surges to $84.9M on BMS license

## Summary
- Net income of $21.9M ($0.38 diluted EPS) vs net loss of $45.8M in Q3 2022; first nine months net loss of $79.6M.
- Revenue of $84.9M, primarily from $72.9M collaboration revenue from BMS tau license including $55M option fee.
- Cash and restricted cash $673.1M at Sept 30, 2023; guidance for year-end ~$600M.
- Upcoming milestones: PRX012 Phase 1 data by year-end 2023; AFFIRM-AL topline in 2024; prasinezumab Phase 2b in 2024.
- R&D expenses rose to $57.9M (+45% YoY) due to higher clinical trial costs.

## SEC filing metadata
- accession: 0001559053-23-000031
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905323000031/0001559053-23-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905323000031/prta-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-23-000031
- JSON: https://secwatch.observer/filing/0001559053-23-000031.json
- Plain text: https://secwatch.observer/filing/0001559053-23-000031.txt

## Key facts
- Earnings Releases
  PROTHENA CORP PUBLIC LTD CO reported third quarter ended September 30, 2023 results: revenue 84.9 million, net income 21.9 million, EPS 0.38.
  - Period: third quarter ended September 30, 2023
  - Revenue: 84.9 million
  - Net income: 21.9 million
  - EPS: 0.38
  - Result: reported results
  source text: Prothena reported net income of $21.9 million and net loss of $79.6 million , respectively, as compared to a net loss o f $45.8 million and $123.3 million for the third quarter and first nine months of 2022, respectively. Net income per share on a diluted basis for the third quarter was $0.38 and net loss per share for the first nine months of 2023 was $1.50 , a s compared to net loss per share of $0.97 and $2.63 f or the third quarter and first nine months of 2022, respectively. Prothena reported total revenue of $84.9 million and $91.1 million for the third quarter and first nine months of 2023, respectively, as compared to total revenue of $1.5 million and $4.0 million for the third quarter and first nine months of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1559053/000155905323000031/0001559053-23-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.